Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
S Fig. 6ab
McCluskey KE et al. (2025)
|
Xtr Wt + chd2 MO
NF20 (in situ hybridization)
|
|
|
|
S Fig. 6ab
McCluskey KE et al. (2025)
|
Xtr Wt + chd8 MO
NF20 (in situ hybridization)
|
|
|
|
SFig. 5a
McCluskey KE et al. (2025)
|
Xtr Wt + dyrk1a CRISPR
NF15 (in situ hybridization)
|
|
|
|
SFig5a
McCluskey KE et al. (2025)
|
Xtr Wt + dyrk1a MO
NF15 (in situ hybridization)
|
|
|
|
Fig. 6 ab
McCluskey KE et al. (2025)
|
Xtr Wt + syngap1 MO
NF20 (in situ hybridization)
|
|
|
|
Fig 6 Ar1 B
Devotta A et al. (2023)
|
Xla Wt + nppa MO
NF15 (in situ hybridization)
|
|
|
|
Fig 6 A:r3 BDE
Devotta A et al. (2023)
|
Xla Wt + nppc MO
NF15 (in situ hybridization)
|
|
|
|
Fig. 5 B:c2r1 CD
Devotta A et al. (2023)
|
Xla Wt + npr1 MO
NF15 (in situ hybridization)
|
|
|
|
Fig. 2 CD
Devotta A et al. (2023)
|
Xla Wt + npr3 MO
NF15 (in situ hybridization)
|
|
|
|
Fig. S6 FGH
Mishra-Gorur K et al. (2023)
|
Xtr wt + Tg(traf)T601A
NF16-18 (in situ hybridization)
|
|
|